← Back

Nanjing Well Pharmaceutical Co Ltd

Nanjing Well Pharmaceutical Group Co., Ltd. is engaged in the research, development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to pharmaceutical companies in China and internationally. Its excipients serve injection, oral, and topical applications, and it also offers active pharmaceutical ingredients such as polidocanol and polyethylene glycol 3350/4000. The company provides a range of synthetic lubricating base oils, additives, and specialty chemicals, as well as products from its Yangzhou well and research institute, including various fatty acids and their esters. Formerly known as Nanjing Well Pharmaceutical Co., Ltd., it changed its name to Nanjing Well Pharmaceutical Group Co., Ltd. in April 2020 and was founded in 2000, based in Nanjing, China.

Country
Price · split & dividend adjusted
News & notes moving 603351.CG
Hong Kong SAR ChinaChina
Electrification & Mobility▲

New World Development Widens Loss in Fiscal Year Ending June 2026, Exits Hong Kong Airport Project

New World Development's loss widened in its fiscal year ending June 2026. Core operating profit rose 28 percent, but the company withdrew from a Hong Kong airport development project to prioritize financial improvement and increased its credit facility to 4.9 billion Hong Kong dollars. On the Chinese mainland, Anhui Jianghuai Automobile Group signaled intent to collaborate with Huawei and Stellantis, Xinjiang Tianye plans to acquire four mining companies for 865 million yuan, and the controlling shareholder of Guangdong Dongyangguang Technology Holding is set to increase its stake by 600 million to 1.2 billion yuan. Nanjing Weier Pharmaceutical Group plans to buy back 50 million to 100 million yuan of its own shares, while the major shareholder of Shaanxi Beiyuan Chemical Group will sell up to 5.5 percent of its shares. In Hong Kong, Li Auto's September deliveries fell 6 percent, and 14 mainland-listed companies have shelved or postponed Hong Kong listings so far this year.
About megatrends
Electrification & Mobility › Passenger EV OEMs (BEV / PHEV) ▼Capital
Electrification & Mobility › China NEV Leaders Capital
0017.HK · Capital · Negative Loss widened for fiscal year ending June 2026 and it withdrew from a Hong Kong airport development project.
2015.HK · Demand · Negative Li Auto's September deliveries fell 6 percent.
603351.CG · Capital · Positive Nanjing Weier Pharmaceutical plans to buy back 50-100 million yuan of its own shares.
600075.CG · Capital · Neutral Plans to acquire four mining companies for 865 million yuan, an M&A move of unclear benefit.
600418.CG · · Neutral Signaled intent to collaborate with Huawei and Stellantis, but no concrete deal or terms.
Read original ↗
トレーダーズ・ウェブ·5dRead more →
China
603351.CG▲

Weier Pharmaceutical Plans to Buy Back Shares Worth 50 Million to 100 Million Yuan

Weier Pharmaceutical announced that the company plans to buy back shares worth 50 million to 100 million yuan, to be used for future employee stock ownership plans or equity incentives, with a buyback price not exceeding 40.11 yuan per share.
603351.CG · Capital · Positive Weier Pharmaceutical plans to buy back 50-100 million yuan of shares for employee stock ownership/equity incentives.
Read original ↗
603351.CG3

Weier Pharmaceutical Releases 2026 Interim Report with Net Profit of 76.7829 Million Yuan

Weier Pharmaceutical released its 2026 interim report on August 22, 2026. The company's total operating revenue was 740 million yuan, net profit attributable to the parent company was 76.7829 million yuan, and net cash inflow from operating activities was 94.053 million yuan. The company's latest asset-liability ratio was 26.56%, gross margin was 27.61%, down 0.46 percentage points from the same period last year, latest ROE was 4.29%, and diluted earnings per share was 0.57 yuan. The company's latest total asset turnover was 0.29 times, inventory turnover was 2.55 times, number of shareholders was 5,464, and the top ten shareholders held 90.508 million shares, accounting for 66.83% of total share capital.
603351.CG · Capital · Neutral Interim report shows net profit and revenue, but no comparative expectations or market reaction; impact unclear.
Read original ↗
Jiemian·45dRead more →